Publications en collaboration avec des chercheurs de Maastricht University (27)

2024

  1. Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies

    Journal of neurology, Vol. 271, Núm. 1, pp. 472-485

2023

  1. Comparison of the Accuracy of the 7-Item HADS Depression Subscale and 14-Item Total HADS for Screening for Major Depression: A Systematic Review and Individual Participant Data Meta-Analysis

    Psychological Assessment, Vol. 35, Núm. 2, pp. 94-114

  2. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

    Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 29, Núm. 7, pp. 875-883

  3. The current clinical practice for management of post-infarction ventricular septal rupture: a European survey

    European Heart Journal Open, Vol. 3, Núm. 5

2022

  1. Endurance Time during Constant Work Rate Cycle Ergometry in COPD: Development of an Integrated Database from Interventional Studies

    Chronic Obstructive Pulmonary Diseases, Vol. 9, Núm. 4, pp. 520-537

  2. ISARIC-COVID-19 dataset: A Prospective, Standardized, Global Dataset of Patients Hospitalized with COVID-19

    Scientific Data, Vol. 9, Núm. 1

2021

  1. Electrocardiographic Imaging for Atrial Fibrillation: A Perspective From Computer Models and Animal Experiments to Clinical Value

    Frontiers in Physiology, Vol. 12

  2. Management of anaphylaxis due to COVID-19 vaccines in the elderly

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 76, Núm. 10, pp. 2952-2964

  3. Systematic review with meta-analysis: effect of inflammatory bowel disease therapy on lipid levels

    Alimentary Pharmacology and Therapeutics, Vol. 54, Núm. 8, pp. 999-1012

  4. The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group

    npj Breast Cancer, Vol. 7, Núm. 1

2020

  1. Beta-blocker effect on ST-segment: A prespecified analysis of the EARLY-BAMI randomised trial

    Open Heart, Vol. 7, Núm. 2

  2. Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population

    Clinical and Translational Oncology, Vol. 22, Núm. 10, pp. 1857-1866

  3. Palliative care for people living with heart failure: European Association for Palliative Care Task Force expert position statement

    Cardiovascular Research, Vol. 116, Núm. 1, pp. 12-27

2019

  1. Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2109-2119

2018

  1. Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia

    Annals of Neurology, Vol. 84, Núm. 5, pp. 729-740

2017

  1. European vignettes in donation after circulatory death

    Progress in Transplantation, Vol. 27, Núm. 3, pp. 286-290

2016

  1. Do self-management interventions work in patients with heart failure? An individual patient data meta-analysis

    Circulation, Vol. 133, Núm. 12, pp. 1189-1198

  2. Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: Primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)

    Annals of Oncology, Vol. 27, Núm. 9, pp. 1719-1725

2015

  1. ESPEN endorsed recommendations: Definition and classification of intestinal failure in adults

    Clinical Nutrition, Vol. 34, Núm. 2, pp. 171-180

2014

  1. The pharmacokinetics of everolimus in de novo kidney transplant patients receiving tacrolimus: An analysis from the randomized ASSET study

    Annals of Transplantation, Vol. 19, Núm. 1, pp. 337-345